Abstract: An atomizer and an electronic atomization device are provided. The atomizer includes: a liquid guide element that includes an atomization surface and a liquid absorbing surface; a heating element for heating a liquid substrate absorbed by the liquid guide element to generate an aerosol; and a first bracket that includes a partition portion, a first chamber and a second chamber. The partition portion isolates the first chamber from the second chamber, and includes a first through hole communicating the first chamber with the second chamber. The liquid guide element is at least partially accommodated in the second chamber. The atomization surface faces the first chamber, and the atomization surface is for the aerosol to escape and enter the first chamber through the first through hole.

Abstract: An ultrasonic atomization assembly, an ultrasonic atomizer, and an ultrasonic atomization device are provided. The ultrasonic atomization assembly includes an ultrasonic atomization sheet including a first electrode and a second electrode; a first liquid guide element in contact with the ultrasonic atomization sheet and configured to transfer a liquid substrate to the ultrasonic atomization sheet; and an atomization sleeve including a limiting portion. One end of the atomization sleeve is provided with an opening. A part of the first liquid guide element is exposed to the opening, and the other part of the first liquid guide element is held between the limiting portion and the ultrasonic atomization sheet. The ultrasonic atomization sheet and the liquid guide element are accommodated in the atomization sleeve and a part of the liquid guide element is exposed to the opening at the end of the atomization sleeve.

Abstract: The present invention relates to the technical field of medicine and relates to an instant release pharmaceutical preparation of an anticoagulant and a preparation method therefor. The instant release pharmaceutical preparation of an anticoagulant comprises a vicagrel compound or a pharmaceutically acceptable form thereof, the preparation is a tablet or a capsule, the vicagrel or the pharmaceutically acceptable form thereof is provided at a suitable particle size, and the D90 thereof <50 ?m. With regard to the drug-containing particles obtained by the present invention, a pharmaceutical preparation formed therefrom exhibits rapid release characteristics in an in vitro dissolution test and exhibits considerable advantages in pharmacokinetics in vivo, showing a greater degree (AUC) and rate (Cmax) of drug absorption.

Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as described herein: Frther provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, D, R1 to R4, and R6 to R10 are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: An ultrasonic atomizer and an ultrasonic atomization device are provided. The ultrasonic atomizer includes a housing internally provided with a liquid storage cavity; a liquid guide element; an ultrasonic atomization sheet including an atomization surface and configured to ultrasonically atomize a liquid substrate absorbed by the liquid guide element to generate an aerosol; and a sealing member configured to seal at least a part of the liquid storage cavity, where the sealing member is further configured to stay in contact with at least a part of the liquid guide element and abut the at least a part of the liquid guide element against the atomization surface. In the ultrasonic atomizer, the sealing member of the liquid storage cavity is utilized to directly abut against the liquid guide element, so that the liquid guide element can be in close contact with the atomization surface of the ultrasonic atomization sheet.

Abstract: A data swapping method is provided. The data swapping method is applied to a host. An operating system and a target application are installed on the host. The operating system includes user space. A user interface of the target application is disposed in the user space. The user interface corresponds to one storage device. A specific solution includes: The host obtains a swap request of the target application, and calls, based on the swap request, the user interface to perform an operation on the storage device. The swap request is a swap-in request or a swap-out request. The swap-out request is used to request to write data of the target application from a memory of the host to the storage device. The swap-in request is used to request to write data in the storage device to the memory.

Abstract: The present invention relates to the technical field of medicine and relates to an instant release pharmaceutical preparation of an anticoagulant and a preparation method therefor. The instant release pharmaceutical preparation of an anticoagulant comprises a vicagrel compound or a pharmaceutically acceptable form thereof, the preparation is a tablet or a capsule, the vicagrel or the pharmaceutically acceptable form thereof is provided at a suitable particle size, and the D90 thereof <50 ?m. With regard to the drug-containing particles obtained by the present invention, a pharmaceutical preparation formed therefrom exhibits rapid release characteristics in an in vitro dissolution test and exhibits considerable advantages in pharmacokinetics in vivo, showing a greater degree (AUC) and rate (Cmax) of drug absorption.

Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, D, R1 to R4, and R6 to R10 are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The invention provides novel heteroaryl-substituted imidazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A and R1 to R6 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The present invention discloses a protein regulating nitrogen-use efficiency and yield of a plant and the use thereof. The present invention obtains a transgenic OsTCP19 rice and a rice OsTCP19 mutant by means of a transgenic technique and a CRISPR-Cas9 technique, respectively. Experiments have shown that compared with wild-type rice, the transgenic OsTCP19 rice has a reduced tiller number and a decreased nitrogen response ability, whereas compared with the wild-type rice, the rice OsTCP19 mutant has an increased tiller number. This indicates that the OsTCP19 protein has the function of regulating the plant yield and nitrogen-use efficiency, thus laying the foundation for cultivating varieties with a high yield and a high nitrogen-use efficiency.

Abstract: The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R7 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R9 and p are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A and R1-R7 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: This application provides an e-cigarette vaporizer and an e-cigarette. The e-cigarette vaporizer includes an outer housing including an open end and an end cap arranged at the open end, where a liquid storage cavity and a sealing base configured to seal the liquid storage cavity are provided in the outer housing; a sealing ring is arranged between the end cap and the outer housing; a vaporization cavity is provided between the sealing ring and the sealing base, and the liquid substrate is vaporized in the vaporization cavity to generate aerosol released to the vaporization cavity; and a plurality of liquid storage grooves configured to adsorb and hold aerosol condensate are provided in the vaporization cavity. The e-cigarette vaporizer uses the liquid storage groove for absorbing the condensate through the capillary action, and prevents the condensate from being taken out along with inhaling airflow during inhaling.

Abstract: The invention provides novel imidazopyrazine derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X1 to X4, R1 to R5, R8 to R10, A, and L1 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein Rx and R3 to R5 are as described herein: or pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, D, R1 to R4, and R6 to R10 are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The present invention relates to the technical field of medicine and relates to an instant release pharmaceutical preparation of an anticoagulant and a preparation method therefor. The instant release pharmaceutical preparation of an anticoagulant comprises a vicagrel compound or a pharmaceutically acceptable form thereof, the preparation is a tablet or a capsule, the vicagrel or the pharmaceutically acceptable form thereof is provided at a suitable particle size, and the D90 thereof <50 ?m. With regard to the drug-containing particles obtained by the present invention, a pharmaceutical preparation formed therefrom exhibits rapid release characteristics in an in vitro dissolution test and exhibits considerable advantages in pharmacokinetics in vivo, showing a greater degree (AUC) and rate (Cmax) of drug absorption.

Abstract: Disclosed in the present invention are a pyrazolo [1,5-a]pyrimidine derivative having a structure of formula (I), a pharmaceutical composition comprising the compound of formula (I), and use of the compound in the preparation of a medicament for preventing or treating diseases associated with tropomyosin receptor kinases, in particular for preventing or treating cancers associated with tropomyosin receptor kinases. Each substituent in formula (I) has the same definition as that in the description.